ImmunityBio, Inc. (IBRX) stock forecast and price target
Price $6.02 · data as of November 13, 2026
12-month price target
Average target$14.25
Upside / downside+136.7%
Analysts4
ConsensusStrong buy
Low $12.00Average $14.25High $16.00
Gold marker: average target · white marker: today’s price ($6.02)
Analyst ratings
Strong buy 1Buy 3Hold 0Sell 0Strong sell 0
Earnings and revenue estimates
| Period | EPS estimate | EPS growth | Revenue estimate |
|---|---|---|---|
| Current fiscal year ends December 31, 2026 | $-0.93 | −144.7% | $202M |
| Next fiscal year ends December 31, 2027 | $-0.36 | — | $352M |
| Quarter after ends March 31, 2027 | $-0.08 | +4.8% | $69M |
Consensus of the analysts covering ImmunityBio, updated daily. In the last 30 days 1 estimates were raised and 1 lowered.
Frequently asked questions
What is the ImmunityBio stock price target?
The average 12-month target from 4 analysts is $14.25, 136.7% above the current price of $6.02 Targets range from $12.00 to $16.00.
Is ImmunityBio a buy according to analysts?
The consensus rating is “Strong buy” (1 strong buy, 3 buy). Ratings are opinions, not guarantees; this is not investment advice.
How much is ImmunityBio expected to earn?
Analysts expect EPS of $-0.93 for the fiscal year ending December 31, 2026 and $-0.36 the year after.
Analyst consensus estimates and price targets, updated daily. Forecasts can be wrong; this is information, not investment advice.